Synthesis, Anti-Bacterial and Molecular Docking Studies of Arylated Butyl 2-Bromoisonicotinate Against Clinical Isolates of ESBL-Producing Escherichia coli ST405 and Methicillin-Resistant Staphylococcus aureus
Shazia Naheed,1 Irum Umar Din,1 Muhammad Usman Qamar,2 Nasir Rasool,1 Matloob Ahmad,1 Muhammad Bilal,1 Aqsa Khalid,3 Gulraiz Ahmad,1 Sami A Al-Hussain,4 Magdi EA Zaki4 1Department of Chemistry, Government College University Faisalabad, Faisalabad, 38000, Pakistan; 2Institute of Microbiology, Faculty...
Published in: | Infection and Drug Resistance |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Dove Press
2023
|
Subjects: | |
Online Access: | https://www.dovepress.com/synthesis-anti-bacterial-and-molecular-docking-studies-of-arylated-but-peer-reviewed-fulltext-article-IDR |
id |
ftdovepress:oai:dovepress.com/85876 |
---|---|
record_format |
openpolar |
spelling |
ftdovepress:oai:dovepress.com/85876 2023-09-05T13:22:56+02:00 Synthesis, Anti-Bacterial and Molecular Docking Studies of Arylated Butyl 2-Bromoisonicotinate Against Clinical Isolates of ESBL-Producing Escherichia coli ST405 and Methicillin-Resistant Staphylococcus aureus Naheed,Shazia Din,Irum Umar Qamar,Muhammad Usman Rasool,Nasir Ahmad,Matloob Bilal,Muhammad Khalid,Aqsa Ahmad,Gulraiz Al-Hussain,Sami A Zaki,Magdi EA 2023-08-14 text/html https://www.dovepress.com/synthesis-anti-bacterial-and-molecular-docking-studies-of-arylated-but-peer-reviewed-fulltext-article-IDR en eng Dove Press info:eu-repo/semantics/altIdentifier/doi/10.2147/IDR.S407891 https://www.dovepress.com/synthesis-anti-bacterial-and-molecular-docking-studies-of-arylated-but-peer-reviewed-fulltext-article-IDR info:eu-repo/semantics/openAccess Infection and Drug Resistance Original Research info:eu-repo/semantics/article 2023 ftdovepress https://doi.org/10.2147/IDR.S407891 2023-08-20T17:36:40Z Shazia Naheed,1 Irum Umar Din,1 Muhammad Usman Qamar,2 Nasir Rasool,1 Matloob Ahmad,1 Muhammad Bilal,1 Aqsa Khalid,3 Gulraiz Ahmad,1 Sami A Al-Hussain,4 Magdi EA Zaki4 1Department of Chemistry, Government College University Faisalabad, Faisalabad, 38000, Pakistan; 2Institute of Microbiology, Faculty of Life Sciences, Government College University, Faisalabad, 38000, Pakistan; 3School of Interdisciplinary Engineering & Science (SINES), National University of Sciences and Technology (NUST), Islamabad, 44000, Pakistan; 4Department of Chemistry, Faculty of Science, Imam Mohammad Ibn Saud Islamic University, Riyad, 11623, Saudi ArabiaCorrespondence: Nasir Rasool; Magdi E A Zaki, Email nasirrasool@gcuf.edu.pk; mezaki@imamu.edu.saIntroduction: Global public health concerns include the emergence and spread of methicillin-resistant Staphylococcus aureus (MRSA) and extended-spectrum beta-lactamase Escherichia coli (ESBL-E. coli). These pathogens cause infections that are difficult to treat, which can have fatal outcomes and require lengthy hospital stays. As a result, we created butyl 2-bromoisonicotinate and tested its antibacterial effectiveness against the ESBL-E. coli ST 405 and MRSA pathogens. Natural product discovery is complemented by synthetic compound synthesis because of the latter’s potential for superior characteristics, target specificity, scalability, intellectual advantages, and chemical diversity. Because of this, the potential for discovering new medicinal compounds is increased, and the constraints placed on natural sources are overcome. Natural items are tough to obtain since they are hard to isolate and synthesize. Therefore, modern science is actively searching for small molecules as therapeutic agents by applying sustainable techniques that can be commercialized.Methods: Two patients’ blood samples were taken, and the BACTEC/Alert system was used to process them. On blood and MacConkey agar, the positive samples were subcultured and incubated aerobically at 37 °C. Using the VITEK 2 compact ... Article in Journal/Newspaper sami Dove Medical Press Infection and Drug Resistance Volume 16 5295 5308 |
institution |
Open Polar |
collection |
Dove Medical Press |
op_collection_id |
ftdovepress |
language |
English |
topic |
Infection and Drug Resistance |
spellingShingle |
Infection and Drug Resistance Naheed,Shazia Din,Irum Umar Qamar,Muhammad Usman Rasool,Nasir Ahmad,Matloob Bilal,Muhammad Khalid,Aqsa Ahmad,Gulraiz Al-Hussain,Sami A Zaki,Magdi EA Synthesis, Anti-Bacterial and Molecular Docking Studies of Arylated Butyl 2-Bromoisonicotinate Against Clinical Isolates of ESBL-Producing Escherichia coli ST405 and Methicillin-Resistant Staphylococcus aureus |
topic_facet |
Infection and Drug Resistance |
description |
Shazia Naheed,1 Irum Umar Din,1 Muhammad Usman Qamar,2 Nasir Rasool,1 Matloob Ahmad,1 Muhammad Bilal,1 Aqsa Khalid,3 Gulraiz Ahmad,1 Sami A Al-Hussain,4 Magdi EA Zaki4 1Department of Chemistry, Government College University Faisalabad, Faisalabad, 38000, Pakistan; 2Institute of Microbiology, Faculty of Life Sciences, Government College University, Faisalabad, 38000, Pakistan; 3School of Interdisciplinary Engineering & Science (SINES), National University of Sciences and Technology (NUST), Islamabad, 44000, Pakistan; 4Department of Chemistry, Faculty of Science, Imam Mohammad Ibn Saud Islamic University, Riyad, 11623, Saudi ArabiaCorrespondence: Nasir Rasool; Magdi E A Zaki, Email nasirrasool@gcuf.edu.pk; mezaki@imamu.edu.saIntroduction: Global public health concerns include the emergence and spread of methicillin-resistant Staphylococcus aureus (MRSA) and extended-spectrum beta-lactamase Escherichia coli (ESBL-E. coli). These pathogens cause infections that are difficult to treat, which can have fatal outcomes and require lengthy hospital stays. As a result, we created butyl 2-bromoisonicotinate and tested its antibacterial effectiveness against the ESBL-E. coli ST 405 and MRSA pathogens. Natural product discovery is complemented by synthetic compound synthesis because of the latter’s potential for superior characteristics, target specificity, scalability, intellectual advantages, and chemical diversity. Because of this, the potential for discovering new medicinal compounds is increased, and the constraints placed on natural sources are overcome. Natural items are tough to obtain since they are hard to isolate and synthesize. Therefore, modern science is actively searching for small molecules as therapeutic agents by applying sustainable techniques that can be commercialized.Methods: Two patients’ blood samples were taken, and the BACTEC/Alert system was used to process them. On blood and MacConkey agar, the positive samples were subcultured and incubated aerobically at 37 °C. Using the VITEK 2 compact ... |
format |
Article in Journal/Newspaper |
author |
Naheed,Shazia Din,Irum Umar Qamar,Muhammad Usman Rasool,Nasir Ahmad,Matloob Bilal,Muhammad Khalid,Aqsa Ahmad,Gulraiz Al-Hussain,Sami A Zaki,Magdi EA |
author_facet |
Naheed,Shazia Din,Irum Umar Qamar,Muhammad Usman Rasool,Nasir Ahmad,Matloob Bilal,Muhammad Khalid,Aqsa Ahmad,Gulraiz Al-Hussain,Sami A Zaki,Magdi EA |
author_sort |
Naheed,Shazia |
title |
Synthesis, Anti-Bacterial and Molecular Docking Studies of Arylated Butyl 2-Bromoisonicotinate Against Clinical Isolates of ESBL-Producing Escherichia coli ST405 and Methicillin-Resistant Staphylococcus aureus |
title_short |
Synthesis, Anti-Bacterial and Molecular Docking Studies of Arylated Butyl 2-Bromoisonicotinate Against Clinical Isolates of ESBL-Producing Escherichia coli ST405 and Methicillin-Resistant Staphylococcus aureus |
title_full |
Synthesis, Anti-Bacterial and Molecular Docking Studies of Arylated Butyl 2-Bromoisonicotinate Against Clinical Isolates of ESBL-Producing Escherichia coli ST405 and Methicillin-Resistant Staphylococcus aureus |
title_fullStr |
Synthesis, Anti-Bacterial and Molecular Docking Studies of Arylated Butyl 2-Bromoisonicotinate Against Clinical Isolates of ESBL-Producing Escherichia coli ST405 and Methicillin-Resistant Staphylococcus aureus |
title_full_unstemmed |
Synthesis, Anti-Bacterial and Molecular Docking Studies of Arylated Butyl 2-Bromoisonicotinate Against Clinical Isolates of ESBL-Producing Escherichia coli ST405 and Methicillin-Resistant Staphylococcus aureus |
title_sort |
synthesis, anti-bacterial and molecular docking studies of arylated butyl 2-bromoisonicotinate against clinical isolates of esbl-producing escherichia coli st405 and methicillin-resistant staphylococcus aureus |
publisher |
Dove Press |
publishDate |
2023 |
url |
https://www.dovepress.com/synthesis-anti-bacterial-and-molecular-docking-studies-of-arylated-but-peer-reviewed-fulltext-article-IDR |
genre |
sami |
genre_facet |
sami |
op_relation |
info:eu-repo/semantics/altIdentifier/doi/10.2147/IDR.S407891 https://www.dovepress.com/synthesis-anti-bacterial-and-molecular-docking-studies-of-arylated-but-peer-reviewed-fulltext-article-IDR |
op_rights |
info:eu-repo/semantics/openAccess |
op_doi |
https://doi.org/10.2147/IDR.S407891 |
container_title |
Infection and Drug Resistance |
container_volume |
Volume 16 |
container_start_page |
5295 |
op_container_end_page |
5308 |
_version_ |
1776203509173059584 |